A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Inclusion Criteria:

- Age ≥18 years

- Histologically or cytologically documented NSCLC with resectable (Stage IIA to select
[ie, N2] Stage IIIB) disease

- World Health Organization (WHO)/ECOG PS of 0 or 1 at enrollment

- At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 Target
Lesion (TL) at baseline

- No prior exposure to immune-mediated therapy including, but not limited to, other
anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic
anticancer vaccines

- Adequate organ and marrow function

- Confirmation of a patients tumour PD-L1 status

- Documented EGFR and ALK status

Exclusion Criteria:

- History of allogeneic organ transplantation

- Active or prior documented autoimmune or inflammatory disorders (including
inflammatory bowel disease, diverticulitis, systemic lupus erythematosus, Sarcoidosis
syndrome, or Wegener syndrome)

- History of another primary malignancy

- History of active primary immunodeficiency

- Active infection including tuberculosis hepatitis B, or human immunodeficiency virus

- Deemed unresectable NSCLC by multidisciplinary evaluation

- Patients who have pre-operative radiotherapy treatment as part of their care plan

- Patients who have brain metastases or spinal cord compression

- Stage IIIB N3 and Stages IIIC, IVA, and IVB NSCLC

- Mixed small cell and NSCLC histology

- Patients who are candidates to undergo only segmentectomies or wedge resections